Autopsy and Case Reports
https://app.periodikos.com.br/journal/autopsy/article/doi/10.4322/acr.2014.028
Autopsy and Case Reports
Article / Clinical Case Report

Advanced small-cell ovarian carcinoma, hypercalcemic type: a challenging therapeutic entity

Rafael Caparica Bitton; Milena Perez Mak; Tiago Kenji Takahashi; Fernando Nalesso Aguiar; Elias Abdo; Maria Del Pilar Estevez Diz

Downloads: 7
Views: 1492

Abstract

Small-cell ovarian carcinoma (SCOC) is a rare and aggressive neoplasia, predominantly affecting young women who are frequently first diagnosed with advanced stage disease. Platinum-based chemotherapy (ChT) can provide high response rates and rapidly ameliorate symptoms in this scenario. However, progression after chemotherapy usually occurs quickly, leading to high mortality rates. In addition, ChT complications, such as tumor lysis syndrome (TLS) can also occur, jeopardizing the patient’s outcome. We present a case of metastatic SCOC in a 47-year-old patient who achieved tumor response after platinum-based chemotherapy and developed TLS, from which she recovered with supportive treatment. After the second ChT cycle, she developed febrile neutropenia and died 8 weeks after the diagnosis of SCOC. Although SCOC is a chemo-sensitive tumor, short-lived responses and frequent chemotherapy complications lead to a dismal prognosis.
 

Keywords

Ovarian Neoplasms, Carcinoma, Small Cell, Tumor Lysis Syndrome, Drug Therapy

References

Young RH, Oliva E, Scully RE. Small cell carcinoma of the ovary, hypercalcemic type. A clinicopathological analysis of 150 cases. Am J Surg Pathol. 1994;18(11):1102-16. http://dx.doi.org/ [https://doi.org/10.1097/00000478-199411000-00004]. PMid: [PMID:7943531]

Harrison ML, Hoskins P, Du Bois Aet al. Small cell of the ovary, hypercalcemic type—analysis of combined experience and recommendation for management. Gynecol Oncol. 2006;100(2):233-8. http://dx.doi.org/ [https://doi.org/10.1016/j.ygyno.2005.10.024]. PMid: [PMID:16321429]

Dickersin GR, Kline IW, Scully RE. Small cell carcinoma of the ovary with hypercalcemia: a report of eleven cases. Cancer. 1982;49(1):188-97. http://dx.doi.org/ [https://doi.org/10.1002/1097-0142(19820101)49:1<188::AID-CNCR2820490137>3.0.CO;2-D]. PMid: [PMID:6274502]

Folpe AL, Chand EM, Goldblum JR, Weiss SW. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol. 2001;25(8):1061-6. http://dx.doi.org/ [https://doi.org/10.1097/00000478-200108000-00011]. PMid: [PMID:11474291]

Hochberg J, Cairo MS. Tumor lysis syndrome: current perspective. Haematologica. 2008;93(1):9-13. http://dx.doi.org/ [https://doi.org/10.3324/haematol.12327]. PMid: [PMID:18166779]

Levitan N, Dowlati A, Remick SCet al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285-91. http://dx.doi.org/ [https://doi.org/10.1097/00005792-199909000-00001]. PMid: [PMID:10499070]

Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010;102(Suppl 1):S2-9. http://dx.doi.org/ [https://doi.org/10.1038/sj.bjc.6605599]. PMid: [PMID:20386546]

Fukuoka M, Furuse K, Saijo Net al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991;83(12):855-61. http://dx.doi.org/ [https://doi.org/10.1093/jnci/83.12.855]. PMid: [PMID:1648142]

Sundstrøm S, Bremnes RM, Kaasa S, et al, and the Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol. 2002;20(24):4665-72. http://dx.doi.org/ [https://doi.org/10.1200/JCO.2002.12.111]. PMid: [PMID:12488411]

Dykgraaf RH, de Jong D, van Veen M, Ewing-Graham PC, Helmerhorst TJ, van der Burg ME. Clinical management of ovarian small-cell carcinoma of the hypercalcemic type: a proposal for conservative surgery in an advanced stage of disease. Int J Gynecol Cancer. 2009;19(3):348-53. http://dx.doi.org/ [https://doi.org/10.1111/IGC.0b013e3181a1a116]. PMid: [PMID:19407558]

Reed WC. Small cell carcinoma of the ovary with hypercalcemia: report of a case of survival without recurrence 5 years after surgery and chemotherapy. Gynecol Oncol. 1995;56(3):452-5. http://dx.doi.org/ [https://doi.org/10.1006/gyno.1995.1081]. PMid: [PMID:7705685]

Rovithi M, Pallis AG, Kalykaki Aet al. Small cell ovarian cancer in adolescents: report of two cases and review of the literature. Case Rep Med. 2011;2011:1-4. http://dx.doi.org/ [https://doi.org/10.1155/2011/749516]. PMid:21738537

Patsner B, Piver MS, Lele SB, Tsukada Y, Bielat K, Castillo NB. Small cell carcinoma of the ovary: a rapidly lethal tumor occurring in the young. Gynecol Oncol. 1985;22(2):233-9. http://dx.doi.org/ [https://doi.org/10.1016/0090-8258(85)90031-9]. PMid: [PMID:2414162]

Pautier P, Ribrag V, Duvillard Pet al. Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type. Ann Oncol. 2007;18(12):1985-9. http://dx.doi.org/ [https://doi.org/10.1093/annonc/mdm376]. PMid: [PMID:17761699]

Shrimali RK, Correa PD, Reed NS. Dose-dense and dose-intense chemotherapy for small cell ovarian cancer: 2 cases and review of literature. Med Oncol. 2011;28(3):766-70. http://dx.doi.org/ [https://doi.org/10.1007/s12032-010-9509-0]. PMid: [PMID:20361360]


 


Publication date:
01/13/2016

569696b564cc8b5cda711c01 autopsy Articles

Autops Case Rep

Share this page
Page Sections